Abstract
Maintenance antipsychotic drug treatment has proven to be of enormous value in preventing psychotic relapse and rehospitalization, as well as in setting the stage for optimal vocational and psychosocial adjustment in patients with schizophrenia. Numerous double-blind, placebo-controlled trials support these conclusions, and several review articles have appeared in recent years summarizing their findings (Davis et al. 1980; Kane and Lieberman 1987).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Crow TJ, McMillan JF, Johnson AL, Johnstone EC (1986) The Northwick Park study of first episodes of schizophrenia. II. A randomized controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 148:120–127
Davis JM, Schaffer CB, Killian GA, Kinard C, Chan C (1980) Important issues in the drug treatment of schizophrenia. Schizophr Bull 6:70–87
Hogarty GE, Schooler NR, Ulrich RF, Mussare F, Ferro P, Herron E (1979) Fluphenazine and social therapy in the aftercare of schizophrenic patients: relapse analysis of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry 36:1283–1294
Kane J (1985) Compliance issues in outpatient treatment. J Clin Psychopharmacol 5:22S–27S
Kane JM, Borenstein M (1985) Compliance in the long-term treatment of schizophrenia. Psychopharmacol Bull 21:23–27
Kane JM, Lieberman JA (1987) Maintenance pharmacotherapy in schizophrenia. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven, New York, pp 1103–1109
Kane JM, Rifkin A, Quitkin F, Nayak DV, Ramos-Lorenzi JR (1982) Fluphenazine versus placebo in patients with remitted, acute first episodes of schizophrenia. Arch Gen Psychiatry 39:70–73
Kane JM, Rifkin A, Woerner M, Reardon G, Sarantakos S, Schiebel D, Ramo-Lorenzi J (1983) Low-dose neuroleptics in the treatment of outpatient schizophrenics. I. Relapse rates, preliminary results. Arch Gen Psychiatry 40:893–896
Kane JM, Woerner M, Borenstein M, Wegner J, Lieberman J (1986) Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 22(l):254–258
Marder SR, van Putten T, Mintz J, McKenzie J, Labelle M, Faltico G, May PRA (1984) Costs and benefits of two doses of fluphenazine. Arch Gen Psychiatry 41:1025–1029
May PRA, Tuma AH, Yale C, Potepan P, Dixson WJ (1976) Schizophrenia — a follow-up study of results of treatment. II. Hospital stay over 2–5 years. Arch Gen Psychiatry 33:481–486
McEvoy JP, Hogerty GE, Steingard S (1990) Optimal dose of neuroleptics in acute schizophrenia: a controlled study of the neuroleptic threshold. (Submitted for publication)
Rabiner CJ, Wegner JT, Kane JM (1986) Outcome study of first-episode psychosis. I. Relapse rates afte one year. Am J Psychiatry 143:1155–1158
Rifkin A, Quitkin F, Rabiner CJ, Klein DF (1977) Fluphenazine decanoate, fluphenazine hydrochloride given orally and placebo in remitted schizophrenics. Arch Gen Psychiatry 34:43–47
Saltz BL, Kane JM, Woerner M, Lieberman JA, Alvir J (1989) Prospective study of tardive dyskinesia in the elderly. Psychopharmacol Bull 25(l):52–59
Schooler NR, Levine J, Severe JB, Brauzer B, DiMascio A, Klerman GL, Tuason VB (1980) Prevention of relapse in schizophrenia: an evaluation of fluphenazine decanoate. Arch Gen Psychiatry 37:16–24
Weiden PJ, Mann JJ, Haas G, Mattson M, Francis A (1986) Clinical nonrecognition of drug-induced movement disorders: a cautionary study. Annual Meeting of the American Psychiatric Association, May, Washington
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Kane, J.M. (1991). Dosage and Route of Administration of Neuroleptic Drugs During Different Phases of a Schizophrenic Illness. In: Kissling, W. (eds) Guidelines for Neuroleptic Relapse Prevention in Schizophrenia. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-86922-8_16
Download citation
DOI: https://doi.org/10.1007/978-3-642-86922-8_16
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-53985-8
Online ISBN: 978-3-642-86922-8
eBook Packages: Springer Book Archive